Lepu Biopharma Co. Ltd. has announced the successful completion of the H Share full circulation, following the issuance of the Filing Notice by the China Securities Regulatory Commission (CSRC) and the subsequent grant of listing approval by the Hong Kong Stock Exchange. The conversion of 54,268,364 unlisted domestic shares into H shares was finalized on July 21, 2025, and the newly converted H shares will begin trading on the Stock Exchange at 9:00 a.m. on July 22, 2025. This development marks a significant milestone in the company's shareholding structure, with H shares now comprising 100% of the company's total share capital, enhancing liquidity and accessibility for investors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lepu Biopharma Co. Ltd. published the original content used to generate this news brief on July 21, 2025, and is solely responsible for the information contained therein.